Brind.
  1. Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.

MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.

2 reports, 2 independent Updated Jun 30
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.

Who's involved

What this event is mainly about
HUMIRAMerck

Keep exploring

Part of

Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • yahoo.com
  • Insider MonkeyMoonLake Immunotherapeutics (MLTX): A Bull Case Theory We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the b